Can-Fite (CANF) director details vested and unvested stock options

Rhea-AI Filing Summary

Can-Fite BioPharma director Abraham Sartani reported existing holdings of stock options to purchase Ordinary Shares. The Form 3 lists multiple option series with different exercise prices and expirations, showing his current derivative position rather than new market trades.

Examples include options over 16 shares at an exercise price of 2826.1400 per share expiring on November 8, 2027, and options over 2,166 shares at 25.2100 per share expiring on April 30, 2033. Another grant covers 16,000 shares at 2.1800 per share expiring on January 25, 2030.

Footnotes state that some grants are fully vested and exercisable, while others vest in scheduled quarterly installments between April 1, 2026 and January 25, 2030, contingent on Sartani’s continued service. Exercise prices were originally set in New Israeli Shekels and are presented here in U.S. dollars using a Bank of Israel exchange rate.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sartani Abraham

(Last) (First) (Middle)

C/O CAN-FITE BIOPHARMA LTD.

26 BEN GURION STREET

(Street)

RAMAT GAN 5257346

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]

3a. Foreign Trading Symbol
[CANF.TA]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(2)	11/08/2017	11/08/2027	Ordinary Shares(2)	16	$2,826.14(3)	D
Options to Purchase Ordinary Shares(1)(4)	08/01/2023	04/30/2033	Ordinary Shares(4)	2,166	$25.21(4)	D
Options to Purchase Ordinary Shares(1)(2)	06/15/2020	06/14/2030	Ordinary Shares(2)	200	$241.47(5)	D
Options to Purchase Ordinary Shares(1)(6)	08/07/2024	05/07/2034	Ordinary Shares(6)	2,166	$26.56(6)	D
Options to Purchase Ordinary Shares(1)(7)	04/25/2026	01/25/2030	Ordinary Shares(7)	16,000	$2.18(7)	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.

2. These options are fully vested and exercisable as of the date hereof.

3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 8778, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.

4. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 677 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

5. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.

6. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

7. The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none of the options are vested, and the remaining 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Abraham Sartani	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Can-Fite (CANF) Form 3 filing by Abraham Sartani show?

The Form 3 shows director Abraham Sartani’s existing holdings of options to purchase Can-Fite Ordinary Shares. It lists several option grants with specific exercise prices, share amounts, and expiration dates, highlighting his current derivative position rather than new buy or sell transactions.

How many option grants are reported for Abraham Sartani in Can-Fite’s Form 3?

The filing reports five separate grants of options to purchase Ordinary Shares. Each grant has its own exercise price, underlying share amount, and expiration date, giving a detailed picture of the director’s compensation-linked equity exposure in Can-Fite BioPharma Ltd. at this time.

What are some key exercise prices in Abraham Sartani’s Can-Fite options?

Key exercise prices include 2826.1400, 241.4700, 26.5600, 25.2100, and 2.1800 per share. These prices were originally set in New Israeli Shekels and converted to U.S. dollars using a Bank of Israel exchange rate disclosed in the footnotes.

Which of Abraham Sartani’s Can-Fite options are vested according to the Form 3?

The filing states some option grants are fully vested and exercisable as of the reporting date. Others are partially vested, with remaining portions scheduled to vest in equal quarterly installments through dates in 2027 and 2028, subject to Sartani’s continued service to Can-Fite.

How do vesting schedules work for Sartani’s 16,000 Can-Fite options?

None of the 16,000 options at an exercise price of 2.1800 per share are vested yet. According to the footnotes, all 16,000 options vest in sixteen equal quarterly installments from April 25, 2026 through January 25, 2030, contingent on continued service.

Why are Can-Fite option exercise prices shown in U.S. dollars on this Form 3?

Exercise prices were originally denominated in New Israeli Shekels under Can-Fite’s share option plans. The Form 3 presents them in U.S. dollars based on a Bank of Israel exchange rate of NIS 3.106 to USD 1.00 reported on March 11, 2026.